The role of celecoxib for treatment of refractory nocturia caused by benign prostatic hyperplasia

الملخص EN

Objective : Nocturia is a well-recognized symptom in patient with benign prostatic hyperplasia (BPH), which is commonly treated by alpha- blocker and / or 5 alpha - reductase inhibitors.

However, the effectiveness of these drugs for nocturia has been reported to be only 25 %- 39 %.

The aim of this study was to investigate the efficacy of celecoxib, a cyclooxygenase -2 inhibitor, in the treatment of patient with BPH complaing of nocturia.

Patients and methods : A prospective study of 50 men with signs tract symptoms and BPH of refractory nocturia to alpha- blocker and / or 5 alpha reductase inhibitor more than two episodes of nocturia per night were involved for nocturia.

Although these patients had received standard drug therapy for more than one month, they had still three or more episodes of nocturia.

The patients took a single dose of 100 mg of celecoxib at night prior to sleep.

And 2 week after the initiation of this therapy, the effects of this treatment were assessed by frequency chart and a questionnaire.

Results : In the questionnaire ,32 of 50 patients (64 %) had an excellent response with celecoxib treatment than previous treatments, 14 of 50 patients (24 %) had an improvement with celecoxib treatment than previous treatments, 4 of 50 patients (8 %) had no response with celecoxib treatment, Nocturnal frequency showed a statistically significant reduction from, baseline after two weeks treatment with celecoxib (P < 0.01), International Prostate Symptom Score(IPSS) showed a statistically significant reduction from baseline after two weeks treatment with celecoxib (P < 0.01), peak flow rate showed a statistically no response from baseline after two weeks treatment with celecoxib (P < 0.05).

Conclusion : Celecoxib is effective in the treatment of patients with BPH complaining of refractory nocturia.

The results suggest a novel treatment option for this common condition.